NetScientific (NSCI) has widened its H1 pretax loss to £6.1m, from a year-earlier restated loss of £4.4m. Revenue was £359,243, from £55,000.
The company's executive chair, Sir Richard Sykes, commented:
"NetScientific has undergone a transformation under the leadership of Francois Martelet, with the rationalisation of the portfolio and restructuring of the management team, resulting in a streamlined Group focused on IP commercialisation.
"The portfolio focus has been totally revitalised with our core portfolio companies, Wanda, Vortex Biosciences, Glycotest and ProAxsis, making excellent progress on their paths towards value realisation."